Biotron Limited Return on Equity

Biotron Limited (BITRF) currently reports a ROE of -62.93%. That is above the Healthcare sector average of -75.59%. Use the charts on this page to explore Biotron Limited's ROE history and peer comparisons.

Biotron Limited's ROE of -62.93% is higher than the Healthcare sector average of -75.59%. That is roughly 16.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' ROE, but Biotron Limited's current -62.93% should be judged against Healthcare norms (sector average: -75.59%) and against BITRF's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current ROE of -62.93%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is -75.59%. From there, open related valuation or income-statement pages for Biotron Limited, and consider following BITRF for alerts when major investors trade the stock.

Biotron Limited is classified in the Healthcare sector. On ROE, it currently shows -62.93% versus a sector average near -75.59%. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing BITRF with unrelated industries.